2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

ABSTRACT

Background

The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium represents an unmissable event for oncologists who deal with renal cell carcinoma (RCC)

Aim and results

This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR–TKI combinations over sunitinib at longer follow–up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF–2α inhibitor belzutifan)

Conclusions

This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.

KEYWORDS:

• Renal cell carcinoma
• 2021 ASCO genitourinary cancer symposium
• first-line
• immunotherapy
• VEGFR-TKI
• HIF-2α inhibitor

Disclosure statement

R. Iacovelli has served as an advisory board member for Pfizer, Janssen, Sanofi, IPSEN, MSD, and Novartis. G Tortora has served on the advisory board for BMS and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper received no funding.